A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

(2017) S. J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment

(2016) Shruti Rao et al.   Oncotarget

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN: Multiple Functions in Human Malignant Tumors

(2015) Michele Milella et al.   Frontiers in Oncology

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma

(2015) Jara Majuelos-Melguizo et al.   Oncotarget

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

(2013) F. Pietrantonio et al.   ANNALS OF ONCOLOGY

Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer

(2013) J. D. Steffen et al.   CANCER RESEARCH

KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials

(2013) Fausto Petrelli et al.   MEDICAL ONCOLOGY

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter

(2013) D. Hochhauser et al.   MOLECULAR CANCER THERAPEUTICS

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours

(2012) A O von Bueren et al.   BRITISH JOURNAL OF CANCER

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells

(2012) D. Minami et al.   MOLECULAR CANCER RESEARCH

Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium

(2011) Toshiro Sato et al.   GASTROENTEROLOGY

Response to Temozolomide in Patients With Metastatic Colorectal Cancer With Loss of MGMT Expression: A New Approach in the Era of Personalized Medicine?

(2011) Einat Shacham-Shmueli et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

(2011) Martin D. Forster et al.   Nature Reviews Clinical Oncology

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

(2010) K. J. Dedes et al.   Science Translational Medicine

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

(2009) F Molinari et al.   BRITISH JOURNAL OF CANCER

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations

(2009) Jeung Il Kim et al.   HUMAN PATHOLOGY

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

(2009) X. Liu et al.   MOLECULAR CANCER RESEARCH

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

(2009) T. M. Horton et al.   MOLECULAR CANCER THERAPEUTICS

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

(2009) M. J. Clarke et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

(2008) O A Khan et al.   BRITISH JOURNAL OF CANCER

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

PTEN: a new guardian of the genome

(2008) Y Yin et al.   ONCOGENE